{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:05:00Z","timestamp":1770458700094,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00198-021-06002-5","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:02:21Z","timestamp":1620936141000},"page":"2377-2381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Denosumab for the treatment of primary pediatric osteoporosis"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"A.D.","family":"Anastasilakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Makras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Doulgeraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Guarnieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"6002_CR1","doi-asserted-by":"publisher","first-page":"1759720X2096926","DOI":"10.1177\/1759720X20969262","volume":"12","author":"SD Sakka","year":"2020","unstructured":"Sakka SD, Cheung MS (2020) Management of primary and secondary osteoporosis in children. Ther Adv Musculoskelet Dis 12:1759720X20969262","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"6002_CR2","first-page":"CD005088","volume":"10","author":"K Dwan","year":"2016","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D (2016) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 10:CD005088","journal-title":"Cochrane Database Syst Rev"},{"key":"6002_CR3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","volume":"15","author":"AM Boyce","year":"2017","unstructured":"Boyce AM (2017) Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep 15:283\u2013292","journal-title":"Curr Osteoporos Rep"},{"key":"6002_CR4","doi-asserted-by":"publisher","first-page":"115048","DOI":"10.1016\/j.bone.2019.115048","volume":"129","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Makras P, Tournis S, Anastasilakis AD (2019) Off-label uses of denosumab in metabolic bone diseases. Bone 129:115048","journal-title":"Bone"},{"key":"6002_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jocd.2014.01.004","volume":"17","author":"N Bishop","year":"2014","unstructured":"Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, Makitie O, Munns CF, Shaw N, International Society of Clinical Densitometry (2014) Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom 17:275\u2013280","journal-title":"J Clin Densitom"},{"key":"6002_CR6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3390\/genes11121513","volume":"11","author":"L Micale","year":"2020","unstructured":"Micale L, Morlino S, Schirizzi A, Agolini E, Nardella G, Fusco C, Castellana S, Guarnieri V, Villa R, Bedeschi MF, Grammatico P, Novelli A, Castori M (2020) Exon-trapping assay improves clinical interpretation of COL11A1 and COL11A2 intronic variants in stickler syndrome type 2 and otospondylomegaepiphyseal dysplasia. Genes (Basel) 11:1513","journal-title":"Genes (Basel)"},{"key":"6002_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/adc.87.4.341","volume":"87","author":"IM van der Sluis","year":"2002","unstructured":"van der Sluis IM, de Ridder MAJ, Boot AM, Krenning EP, de Muinck K-SSMPF (2002) Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child 87:341\u2013347","journal-title":"Arch Dis Child"},{"key":"6002_CR8","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EJE-18-0056","volume":"179","author":"AD Anastasilakis","year":"2018","unstructured":"Anastasilakis AD, Polyzos SA, Makras P (2018) Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol 179:R31\u2013R45","journal-title":"Eur J Endocrinol"},{"key":"6002_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00198-019-05233-x","volume":"31","author":"PD Miller","year":"2020","unstructured":"Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwi\u0144ski E, Bone HG, Wang C, Huang S, Chines A, Lems W, Brown JP (2020) Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int 31:181\u2013191","journal-title":"Osteoporos Int"},{"key":"6002_CR10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"6002_CR11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJMc062792","volume":"356","author":"SE Papapoulos","year":"2007","unstructured":"Papapoulos SE, Cremers SC (2007) Prolonged bisphosphonate release after treatment in children. N Engl J Med 356:1075\u20131076","journal-title":"N Engl J Med"},{"key":"6002_CR12","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00198-020-05676-7","volume":"31","author":"C Camponovo","year":"2020","unstructured":"Camponovo C, Aubry-Rozier B, Lamy O, Gonzalez Rodriguez E (2020) Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. Osteoporos Int 31:2485\u20132491","journal-title":"Osteoporos Int"},{"key":"6002_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13256-020-02401-0","volume":"14","author":"Y Maugars","year":"2020","unstructured":"Maugars Y, Guillot P, Glemarec J, Berthelot JM, Le Goff B, Darrieutort-Laffite C (2020) Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report. J Med Case Rep 14:130","journal-title":"J Med Case Rep"},{"key":"6002_CR14","first-page":"V12170948","volume":"180","author":"L Tjelum","year":"2018","unstructured":"Tjelum L, Eiken P (2018) Multiple vertebral fractures after denosumab discontinuation. Ugeskr Laeger 180:V12170948","journal-title":"Ugeskr Laeger"},{"key":"6002_CR15","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","volume":"27","author":"AS Koldkjaer Solling","year":"2016","unstructured":"Koldkjaer Solling AS, Harslof T, Kaal A, Rejnmark L, Langdahl B (2016) Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int 27:2383\u20132386","journal-title":"Osteoporos Int"},{"key":"6002_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","volume":"9","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O (2014) Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis 9:145","journal-title":"Orphanet J Rare Dis"},{"key":"6002_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3390\/jcm7120479","volume":"7","author":"T Kobayashi","year":"2018","unstructured":"Kobayashi T, Nakamura Y, Suzuki T, Yamaguchi T, Takeda R, Takagi M, Hasegawa T, Kosho T, Kato H (2018) Efficacy and safety of denosumab therapy for osteogenesis imperfecta patients with osteoporosis-case series. J Clin Med 7:479","journal-title":"J Clin Med"},{"key":"6002_CR18","first-page":"76","volume":"18","author":"P Trejo","year":"2018","unstructured":"Trejo P, Rauch F, Ward L (2018) Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 18:76\u201380","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"6002_CR19","doi-asserted-by":"publisher","first-page":"115124","DOI":"10.1016\/j.bone.2019.115124","volume":"132","author":"M Geserick","year":"2020","unstructured":"Geserick M, Vogel M, Eckelt F, Schlingmann M, Hiemisch A, Baber R, Thiery J, Korner A, Kiess W, Kratzsch J (2020) Children and adolescents with obesity have reduced serum bone turnover markers and 25-hydroxyvitamin D but increased parathyroid hormone concentrations - Results derived from new pediatric reference ranges. Bone 132:115124","journal-title":"Bone"},{"key":"6002_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/BF00350961","volume":"16","author":"JP Devogelaer","year":"1987","unstructured":"Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skelet Radiol 16:360\u2013363","journal-title":"Skelet Radiol"},{"key":"6002_CR21","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1210\/jcem-61-5-952","volume":"61","author":"K Hoekman","year":"1985","unstructured":"Hoekman K, Papapoulos SE, Peters AC, Bijvoet OL (1985) Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J Clin Endocrinol Metab 61:952\u2013956","journal-title":"J Clin Endocrinol Metab"},{"key":"6002_CR22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1359\/JBMR.040303","volume":"19","author":"F Rauch","year":"2004","unstructured":"Rauch F, Travers R, Munns C, Glorieux FH (2004) Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 19:1191\u20131193","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06002-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-06002-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06002-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T10:05:35Z","timestamp":1635847535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-06002-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["6002"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-06002-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"assertion":[{"value":"19 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.D. Anastasilakis reports lecture fees from Amgen; P. Makras reports honoraria for lectures and research grants from Amgen; S.A. Polyzos, A. Doulgeraki, and V. Guarnieri have nothing to declare; S. E. Papapoulos has received consulting and speaking fees from Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient\u2019s parents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}